ELABELA protects against diabetic kidney disease by activating high glucose-inhibited renal tubular autophagy

ELABELA (ELA), an endogenous ligand of the apelin receptor (also known as apelin peptide jejunum [APJ]), has been shown to decrease in the plasma of patients with diabetic kidney disease (DKD). In the current study, we explored the potential function as well as the underlying mechanisms of ELA in DK...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Xiyin, Yin, Lulu, Song, Jing, Chen, Juan, Gu, Wensha, Shi, Min, Zhang, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial Department of Journal of Biomedical Research 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10687528/
https://www.ncbi.nlm.nih.gov/pubmed/38018421
http://dx.doi.org/10.7555/JBR.37.20220214

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10687528/
https://www.ncbi.nlm.nih.gov/pubmed/38018421
http://dx.doi.org/10.7555/JBR.37.20220214

Ejemplares similares